Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydralazine
Drug ID BADD_D01081
Description Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.
Marketing Status Prescription; Discontinued
ATC Code C02DB02
DrugBank ID DB01275
KEGG ID D08044
MeSH ID D006830
PubChem ID 3637
TTD Drug ID D0K1XK
NDC Product Code Not Available
Synonyms Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine
Chemical Information
Molecular Formula C8H8N4
CAS Registry Number 86-54-4
SMILES C1=CC=C2C(=C1)C=NN=C2NN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pericarditis02.06.02.0010.001491%
Platelet count decreased13.01.04.0010.000497%
Pleural effusion22.05.02.0020.000663%
Pleuritic pain22.02.04.008--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyneuropathy17.09.03.012--Not Available
Premature baby18.04.02.0010.000994%Not Available
Premature delivery18.07.01.0060.000497%
Premature labour18.07.01.0020.000331%Not Available
Proteinuria20.02.01.0110.000994%
Pruritus23.03.12.0010.001325%
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.003644%Not Available
Pulmonary haemorrhage24.07.01.016; 22.02.04.0030.000173%
Pulmonary oedema22.01.03.003; 02.05.02.0030.000663%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.0010.002153%Not Available
Renal failure20.01.03.0050.000302%Not Available
Renal vasculitis24.05.02.007; 20.01.07.007; 10.02.02.0130.001822%Not Available
Respiratory distress22.02.01.0120.000497%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000828%
Restlessness19.11.02.002; 17.02.05.0210.000331%
Retinal vasculitis10.02.02.021; 06.04.06.0110.000331%Not Available
Retroperitoneal fibrosis20.06.01.006; 10.02.01.026; 07.07.03.003--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Sepsis11.01.11.003--
Sinus tachycardia02.03.03.0100.000497%
Splenomegaly01.09.02.001--Not Available
Strangury20.02.02.017--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages